文献速递肿瘤 PET/CT放射性药物与辐射防护

[18F]AlF-RESCA-HER2-BCH与[18F]AlF-NOTA-HER2-BCH在小鼠和乳腺癌患者中肾脏清除的比较

Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-04-24

研究开发了新型HER2亲和体分子探针[18F]AlF-RESCA-HER2-BCH以降低肾脏摄取,并在HER2阳性胃癌PDX小鼠模型和5例乳腺癌患者中与[18F]AlF-NOTA-HER2-BCH进行比较。结果显示[18F]AlF-RESCA-HER2-BCH在保持肿瘤靶向性的同时,肾脏累积和肾脏吸收剂量均显著低于[18F]AlF-NOTA-HER2-BCH。

要点

  • 小鼠PDX模型中[18F]AlF-RESCA-HER2-BCH肾脏累积显著低于[18F]AlF-NOTA-HER2-BCH(5.16±0.22 vs 158.73±5.44 %ID/g)。
  • 乳腺癌患者中[18F]AlF-RESCA-HER2-BCH肾脏吸收剂量显著低于[18F]AlF-NOTA-HER2-BCH(0.4450±0.1117 vs 0.8030±0.1604 mGy/MBq)。
  • 临床研究中[18F]AlF-RESCA-HER2-BCH在转移灶中靶/非靶比值显著高于[18F]AlF-NOTA-HER2-BCH。

核心结论

  • [18F]AlF-RESCA-HER2-BCH在检测转移灶时倾向于提供更好的图像对比度和更高的靶/非靶比值。
  • [18F]AlF-RESCA-HER2-BCH的肾脏累积低于[18F]AlF-NOTA-HER2-BCH。

研究设计与样本

  • 临床前研究:使用HER2阳性胃癌患者来源异种移植(PDX)模型,注射后0.5-1小时(动态)、2、4、6小时行micro-PET/CT;阻断实验中将0.5 mg冷亲和体与探针共注射;注射后2小时行生物分布研究。
  • 临床研究:5例乳腺癌患者(4例HER2阳性、1例HER2低表达),注射231.29±17.77 MBq [18F]AlF-NOTA-HER2-BCH或[18F]AlF-RESCA-HER2-BCH后2小时和4小时行PET/CT显像,测量肿瘤和源器官的标准化摄取值(SUV)进行半定量分析。
  • 使用OLINDA/EXM软件(版本1.2)计算辐射剂量。

主要发现

  • [18F]AlF-NOTA-HER2-BCH和[18F]AlF-RESCA-HER2-BCH均能稳定标记[18F]F,对HER2具有高结合特异性和亲和力。
  • Micro-PET/CT显示两种探针均能清晰显示HER2阳性PDX肿瘤,注射后2小时摄取分别为16.24±1.74 %ID/g和14.39±2.45 %ID/g。
  • 注射后2小时[18F]AlF-RESCA-HER2-BCH肾脏累积显著低于[18F]AlF-NOTA-HER2-BCH(5.16±0.22 %ID/g vs 158.73±5.44 %ID/g,p<0.0001)。
  • 临床研究中两种探针均显示良好的肿瘤靶向和图像对比度;[18F]AlF-RESCA-HER2-BCH在原发肿瘤和转移灶中SUVmax更高,转移灶靶/非靶比值显著高于[18F]AlF-NOTA-HER2-BCH。
  • [18F]AlF-RESCA-HER2-BCH肾脏累积较低(2小时:43.56±7.88 vs 79.81±3.81,p<0.0001;4小时:33.23±6.89 vs 78.63±4.00,p<0.0001),肾脏吸收剂量也显著低于[18F]AlF-NOTA-HER2-BCH(0.4450±0.1117 mGy/MBq vs 0.8030±0.1604 mGy/MBq,p<0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A novel HER2 affibody-based molecular probe, [18F]AlF-RESCA-HER2-BCH, was developed for reducing renal uptake, evaluated, and compared with [18F]AlF-NOTA-HER2-BCH. METHODS: In preclinical studies, micro-PET/CT was performed using HER2-positive gastric cancer patient-derived xenografts (PDX) model at 0.5-1 (dynamic), 2, 4, and 6 h post-injection. For blocking experiment, 0.5 mg cold affibody was co-injected with probes. Biodistribution were performed on HER2-positive PDX models at 2 h post-injection. For clinical study, PET/CT images were acquired at 2 h and 4 h after injection of 231.29 ± 17.77 MBq [18F]AlF-NOTA-HER2-BCH or [18F]AlF-RESCA-HER2-BCH in five breast cancer patients (4 HER2-positive and 1 HER2-low). Standardized uptake values (SUVs) were measured in tumors and source-organs for semi-quantitative analysis. The OLINDA/EXM software (version 1.2) was used to calculate the radiation doses. RESULTS: [18F]AlF-NOTA-HER2-BCH and [18F]AlF-RESCA-HER2-BCH were stably labeled with [18F]F, with high binding specificity and affinity to HER2. Micro-PET/CT of both tracers could clearly visualize HER2-positive PDX tumors with high uptake of 16.24 ± 1.74% ID/g and 14.39 ± 2.45% ID/g at 2 h post-injection. The renal accumulation of [18F]AlF-RESCA-HER2-BCH was significantly lower than that of [18F]AlF-NOTA-HER2-BCH (5.16 ± 0.22% ID/g vs. 158.73 ± 5.44% ID/g at 2 h, p < 0.0001). In the clinical study, both [18F]AlF-NOTA-HER2-BCH and [18F]AlF-RESCA-HER2-BCH demonstrated favorable tumor targeting and image contrast. [18F]AlF-RESCA-HER2-BCH showed a higher SUVmax in both primary tumor and metastases, and a significantly higher target-to-nontarget ratio in metastases than [18F]AlF-NOTA-HER2-BCH. Moreover, [18F]AlF-RESCA-HER2-BCH had lower renal accumulation (43.56 ± 7.88 vs. 79.81 ± 3.81 at 2 h, p < 0.0001; 33.23 ± 6.89 vs. 78.63 ± 4.00 at 4 h, p < 0.0001) as well as a significantly lower renal absorbed dose than [18F]AlF-NOTA-HER2-BCH (0.4450 ± 0.1117 mGy/MBq vs. 0.8030 ± 0.1604 mGy/MBq, p < 0.01). CONCLUSIONS: [18F]AlF-RESCA-HER2-BCH tended to provide better image contrast than [18F]AlF-NOTA-HER2-BCH with a higher target-to-nontarget ratio in detection of metastases. Notably, [18F]AlF-RESCA-HER2-BCH had lower renal accumulation than [18F]AlF-NOTA-HER2-BCH.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liu J, Guo X, Wen L, et al. Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients. Eur J Nucl Med Mol Imaging. 2023. PMID: 37093312. doi:10.1007/s00259-023-06232-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。